← Back to Search

Vitamin D Production Stimulator

Phototherapy for Multiple Sclerosis

Phase 1
Waitlist Available
Led By Robert W Motl, PhD
Research Sponsored by University of Illinois at Urbana-Champaign
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Female with multiple sclerosis
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0, 4, and 8 weeks

Summary

The current study examines the effect of phototherapy equipped with Narrow Band UVB lamps on vitamin D production in persons with MS.

Eligible Conditions
  • Multiple Sclerosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 4, and 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 4, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline in Serum Vitamin D at 4 and 8 weeks
Secondary study objectives
Change from Baseline in Cognitive Function at 4 and 8 weeks
Change from Baseline in Mood State at 4 and 8 weeks
Change from Baseline in Walking Speed at 4 and 8 weeks

Side effects data

From 2016 Phase 2 trial • 91 Patients • NCT01887327
17%
Cardiac murmur
17%
Erythema
13%
Umbilical hernia
10%
Rash
10%
Seborrhoeic dermatitis
7%
Haemolytic anaemia
7%
Hyperbilirubinaemia
7%
Medical observation
7%
Thrombocytopenia
7%
Haemoglobin decreased
7%
Reticulocyte count increased
7%
Dermatitis diaper
7%
Dry skin
7%
Rash maculo-papular
7%
Gamma-glutamyl transferase increased
7%
Seborrhoea
3%
Haematocrit decreased
3%
Tachypnoea
3%
Anaemia
3%
Conjucunctival Hemorrhage
3%
Cough
3%
Acne infantile
3%
Erythema toxicum neonatorum
3%
Milia
3%
Leukocytosis
3%
Supraventricular Tachycardia
3%
Ventricular Hypertrophy
3%
Ankyloglossia Congenital
3%
Atrial Septal Defect
3%
Patent Ductus Arteriosus
3%
Eye Discharge
3%
Constipation
3%
Infantile Colic
3%
Infantile Vomiting
3%
Vomiting
3%
Candida Nappy Rash
3%
Skin Candida
3%
Viral Infection
3%
Sunburn
3%
Aspartate Aminotransferase Increased
3%
Bilirubin Conjugated Increased
3%
Haematocrit Abnormal
3%
Respiratory Syncytial Virus Test Positive
3%
Hyperkalaemia
3%
Hypocalcaemia
3%
Lethargy
3%
Tremor
3%
Umbilical Granuloma
3%
Nasal Congestion
3%
Melanosis
3%
Rash Erythematous
3%
Skin Hyperpigmentation
3%
Skin Sensitisation
3%
Supraventricular tachycardia
100%
80%
60%
40%
20%
0%
Study treatment Arm
3.0 mg/kg Stannsoporfin
4.5mg/kg Stannsoporfin
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PhototherapyExperimental Treatment1 Intervention
This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
Group II: Shame phototherapyPlacebo Group1 Intervention
This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phototherapy
2021
Completed Phase 4
~750

Find a Location

Who is running the clinical trial?

University of Illinois at Urbana-ChampaignLead Sponsor
197 Previous Clinical Trials
38,255 Total Patients Enrolled
16 Trials studying Multiple Sclerosis
735 Patients Enrolled for Multiple Sclerosis
Robert W Motl, PhDPrincipal InvestigatorUniversity of Illinois at Urbana-Champaign
7 Previous Clinical Trials
851 Total Patients Enrolled
7 Trials studying Multiple Sclerosis
851 Patients Enrolled for Multiple Sclerosis
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top